Dr. Albain, the Huizenga Family Endowed Chair in Oncology Research, is a professor in the Division of Hematology/Oncology in the Department of Medicine of Loyola University Chicago Stritch School of Medicine.Dr. Albain was one of several co-authors of the study conducted at Montefiore Medical Center in the Bronx borough of New York City.She is a member of the international Early Breast Cancer Trialists' Collaborative Group and its Steering Committee.She is also director of Loyola Cardinal Bernardin Cancer Center's breast clinical research program, co-director of the multidisciplinary breast oncology center, and director of the thoracic oncology program.Additionally, she served on the National Cancer Institute Concept Evaluation Panel for lung cancer and was a charter member of the National Institute of Health Committee on Research on Women's Health.An author of nearly 200 publications in peer-reviewed journals and textbooks, she is a fellow of the American College of Physicians and the American Society of Clinical Oncology.
Events - Primer's event detection algorithm clusters and summarizes multiple documents describing real-world events.
Mentions - Mentions are snippets of text that map to a person.
Docs - The number of documents that match to a person in Primer's corpus of news articles.
Full tech explainer here.
Remember to check the sources and follow Wikipedia's guidelines.
Loyola University Medical Center
"With results of this groundbreaking study, we now can safely avoid chemotherapy in about 70% of patients who are diagnosed with the most common form of breast cancer," claims lead trial investigator Kathy Albain, M.D., the Huizenga Family Endowed Chair in Oncology Research at Loyola University Chicago Stritch School of Medicine, who is co-author of the NEJM paper. The prospective TAILORx study was designed to help to discover whether chemotherapy is beneficial for women with a mid-range recurrence score of 11 to 25, as well as to prospectively confirm that a low recurrence score of 0–10 is associated with a low rate of distant recurrence if patients receive endocrine therapy without adjuvant chemotherapy. The trial results showed that for women in the intermediate recurrence score group, endocrine therapy was no less effective than hormone therapy plus chemotherapy at prolonging disease-free survival.
The results of the study showed median air pollution exposure of never-smoker cancer patients was more than double that of ever-smokers with lung cancer. Women with non-small cell lung cancers live longer than men, WCLC study shows Women diagnosed with non-small cell lung cancers live longer than their male counterparts, according to results of a SWOG study presented today by Kathy Albain, M.D., the Huizenga Family Endowed Chair in Oncology Research at Loyola University Chicago Stritch School of Medicine. Regardless of smoking history or any other factor, women in the trial had significantly better overall survival rates compared to men. About the IASLC The International Association for the Study of Lung Cancer is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies.
Black women with a certain type of early-stage breast cancer had a 52 percent higher risk of dying when compared to white women, according to a research presented Thursday at an international breast cancer symposium in San Antonio. When compared against all trial participants, black women overall had 4 percent higher risk of dying or experiencing a recurrence of their cancer. "Higher recurrence and overall mortality rates were observed for blacks versus whites and others despite all were enrolled in the same trial and treated with the same contemporary cancer care," Albain said. As part of the trial, breast cancer patients received treatment based on a scored genetic analysis of their tumors that determined their risk for cancer recurrence.